FI118512B - Flutikasonipropionaattiformuloita - Google Patents

Flutikasonipropionaattiformuloita Download PDF

Info

Publication number
FI118512B
FI118512B FI964634A FI964634A FI118512B FI 118512 B FI118512 B FI 118512B FI 964634 A FI964634 A FI 964634A FI 964634 A FI964634 A FI 964634A FI 118512 B FI118512 B FI 118512B
Authority
FI
Finland
Prior art keywords
formulation
sorbitan monolaurate
formulation according
polyoxyethylene
fluticasone propionate
Prior art date
Application number
FI964634A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI964634A (fi
FI964634A0 (fi
Inventor
David Alexander Tainsh
Trevor Leslie Ilott
Dorothy Jill Snell
Li Fong Lam
Original Assignee
Glaxo Wellcome Australia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Australia Ltd filed Critical Glaxo Wellcome Australia Ltd
Publication of FI964634A publication Critical patent/FI964634A/fi
Publication of FI964634A0 publication Critical patent/FI964634A0/fi
Application granted granted Critical
Publication of FI118512B publication Critical patent/FI118512B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI964634A 1994-05-21 1996-11-20 Flutikasonipropionaattiformuloita FI118512B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9410222A GB9410222D0 (en) 1994-05-21 1994-05-21 Medicaments
GB9410222 1994-05-21
EP9501913 1995-05-19
PCT/EP1995/001913 WO1995031964A1 (en) 1994-05-21 1995-05-19 Fluticasone propionate formulations

Publications (3)

Publication Number Publication Date
FI964634A FI964634A (fi) 1996-11-20
FI964634A0 FI964634A0 (fi) 1996-11-20
FI118512B true FI118512B (fi) 2007-12-14

Family

ID=10755515

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964634A FI118512B (fi) 1994-05-21 1996-11-20 Flutikasonipropionaattiformuloita

Country Status (29)

Country Link
US (1) US5993781A (xx)
EP (1) EP0760649B1 (xx)
JP (1) JPH10500420A (xx)
KR (2) KR100361413B1 (xx)
CN (1) CN1098680C (xx)
AT (1) ATE207734T1 (xx)
AU (1) AU710821B2 (xx)
BR (1) BR9507746A (xx)
CA (1) CA2190763A1 (xx)
CY (1) CY2294B1 (xx)
CZ (1) CZ285966B6 (xx)
DE (1) DE69523587T2 (xx)
DK (1) DK0760649T3 (xx)
ES (1) ES2164767T3 (xx)
FI (1) FI118512B (xx)
GB (1) GB9410222D0 (xx)
HK (1) HK1004192A1 (xx)
HU (1) HU223316B1 (xx)
IL (1) IL113794A (xx)
MX (1) MX9605650A (xx)
NO (1) NO313785B1 (xx)
NZ (1) NZ287425A (xx)
PL (1) PL180318B1 (xx)
PT (1) PT760649E (xx)
RU (1) RU2161485C2 (xx)
SI (1) SI0760649T1 (xx)
TW (1) TW438604B (xx)
WO (1) WO1995031964A1 (xx)
ZA (1) ZA954101B (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE274341T1 (de) * 1995-02-24 2004-09-15 Elan Pharma Int Ltd Nanopartikel-dispersionen enthaltende aerosole
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
CA2468958C (en) 2001-12-19 2012-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
AU2003210517A1 (en) 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
AU2003246829A1 (en) 2002-02-19 2003-09-09 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
JP2006501936A (ja) * 2002-10-04 2006-01-19 エラン ファーマ インターナショナル，リミティド 固体ナノ粒子活性薬剤のガンマ線照射
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
EP1454636A1 (en) * 2003-03-04 2004-09-08 Dompé S.P.A. Sterilization of glucocorticoid drug particles for pulmonary delivery
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
JP2007501683A (ja) * 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
ATE497787T1 (de) 2004-03-12 2011-02-15 Cipla Ltd Sterilisationsprozess für steroide
GB0410995D0 (en) 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
GB0425266D0 (en) * 2004-11-16 2004-12-15 Norton Healthcare Ltd Pharmaceutical manufacturing process
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2847207B1 (en) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Fluticasone propionate nanocrystals
CN103505412A (zh) * 2012-06-26 2014-01-15 上海臣邦医药科技有限公司 一种吸入用丙酸氟替卡松混悬液的制备方法
WO2014007781A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
DE102012111077A1 (de) * 2012-11-16 2014-05-22 Justus-Liebig-Universität Giessen Optimierung von Vernebelungseigenschaften einer Lösung oder eines Kolloids
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
KR102379309B1 (ko) 2014-09-15 2022-03-28 베로나 파마 피엘씨 Ｒｐｌ５５４를 포함하는 액상 흡입제
JP7470646B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
JP3280974B2 (ja) * 1991-12-12 2002-05-13 グラクソ、グループ、リミテッド 医 薬
DE69232462T2 (de) * 1991-12-18 2002-10-10 Astrazeneca Ab Formoterol und budesonide enthaltende zusammensetzung
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments

Also Published As

Publication number Publication date
CA2190763A1 (en) 1995-11-30
CN1148804A (zh) 1997-04-30
JPH10500420A (ja) 1998-01-13
IL113794A (en) 2000-10-31
CN1098680C (zh) 2003-01-15
ZA954101B (en) 1996-01-29
TW438604B (en) 2001-06-07
BR9507746A (pt) 1997-08-19
AU2614595A (en) 1995-12-18
US5993781A (en) 1999-11-30
DE69523587D1 (de) 2001-12-06
ES2164767T3 (es) 2002-03-01
PL317225A1 (en) 1997-03-17
HK1004192A1 (en) 1998-11-20
CZ342396A3 (en) 1997-07-16
WO1995031964A1 (en) 1995-11-30
CZ285966B6 (cs) 1999-12-15
KR970703132A (ko) 1997-07-03
KR970703130A (ko) 1997-07-03
NO964938D0 (no) 1996-11-20
SI0760649T1 (en) 2002-04-30
ATE207734T1 (de) 2001-11-15
MX9605650A (es) 1998-05-31
NO313785B1 (no) 2002-12-02
NO964938L (no) 1996-11-20
DK0760649T3 (da) 2002-01-28
CY2294B1 (en) 2003-07-04
RU2161485C2 (ru) 2001-01-10
HU223316B1 (hu) 2004-05-28
FI964634A (fi) 1996-11-20
NZ287425A (en) 1998-05-27
HUT76552A (en) 1997-09-29
EP0760649B1 (en) 2001-10-31
PT760649E (pt) 2002-04-29
GB9410222D0 (en) 1994-07-06
HU9603227D0 (en) 1997-01-28
PL180318B1 (pl) 2001-01-31
EP0760649A1 (en) 1997-03-12
IL113794A0 (en) 1995-08-31
KR100361413B1 (ko) 2003-02-19
AU710821B2 (en) 1999-09-30
FI964634A0 (fi) 1996-11-20
DE69523587T2 (de) 2002-06-27

Similar Documents

Publication Publication Date Title
FI118512B (fi) Flutikasonipropionaattiformuloita
AU749751B2 (en) Pulmonary and nasal delivery of raloxifene
US9724382B2 (en) Pharmaceutical compositions comprising cyclosporin
OA11529A (en) Aerosolized active agent delivery.
US20090041676A1 (en) Targeted Delivery of Lidocaine and Other Local Anesthetics and A Method For Treatment of Cough, Asthma and Tussive Attacks
WO2006036180A1 (en) Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
US6187765B1 (en) Mometasone furoate suspensions for nebulization
EP1033991B1 (en) Mometasone furoate suspensions for nebulization
US20050042171A1 (en) Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
CN113350323A (zh) 一种用于抑制冠状病毒的吸入剂及其制备方法和应用
JP6908523B2 (ja) ネブライザー用組成物
US20040039020A1 (en) Novel pharmaceutical formulation suitable for nebulisation
EA042761B1 (ru) Способ лечения заболеваний легких и набор
EA044593B1 (ru) Ингаляционные композиции, содержащие макроциклические иммуносупрессанты
MXPA00009704A (en) Pulmonary and nasal delivery of raloxifene
JPWO2020002351A5 (xx)
CZ20003544A3 (cs) Pulmonární a nasální podávání raloxifenu

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118512

Country of ref document: FI

MA Patent expired